← Back to Search

Phosphodiesterase 5 Inhibitor

Sildenafil Citrate for Post-Concussion Syndrome

Phase 1
Waitlist Available
Research Sponsored by University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up immediate
Awards & highlights

Summary

This trial involves giving sildenafil citrate (Viagra) to patients with repetitive mild traumatic brain injury to improve their brain blood flow. The drug works by relaxing blood vessels, which may help these patients recover better.

Eligible Conditions
  • Concussion
  • Post-Concussion Syndrome
  • Traumatic Brain Injury

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Effect of single dose sildenafil citrate treatment on global blood oxygen level-dependent (BOLD) response to hypercapnia.
Secondary study objectives
Effect of single dose sildenafil citrate treatment on functional near-infrared spectroscopy (fNIRS) response to hypercapnia.
Maximum tolerable dose of sildenafil therapy without severe adverse events.
Other study objectives
Effect of 5 weeks of sildenafil treatment on attention using Trail Making Test Part A.
Effect of 5 weeks of sildenafil treatment on attention using the Digit Symbol Modalities Test.
Effect of 5 weeks of sildenafil treatment on daily function using the Functional Activities Questionnaire.
+7 more

Side effects data

From 2013 Phase 4 trial • 105 Patients • NCT00323297
14%
Diarrhoea
14%
Oedema peripheral
14%
Headache
10%
Bronchitis
10%
Flushing
10%
Nasopharyngitis
10%
Vertigo
10%
Palpitations
8%
Respiratory tract infection
6%
Depression
6%
Right ventricular failure
6%
Dyspnoea
6%
Vision blurred
6%
Presyncope
6%
Pulmonary hypertension
4%
Pulmonary arterial hypertension
4%
Anaemia
4%
Upper respiratory tract infection
4%
Bronchopneumonia
2%
Nausea
2%
Haemoglobin decreased
2%
Cardiac failure
2%
Cardiovascular disorder
2%
Chest discomfort
2%
Haemoptysis
2%
Cough
2%
Acute coronary syndrome
2%
Hypoxia
2%
Death
2%
Coronary artery disease
2%
Skin ulcer
2%
Back pain
2%
Walking distance test abnormal
2%
Pancreatic neoplasm
2%
Breast cancer
2%
Uterine haemorrhage
2%
Mitral valve incompetence
2%
Inguinal hernia
2%
Circulatory collapse
2%
General physical health deterioration
2%
Urinary tract infection
2%
Asthenia
2%
Respiratory syncytial virus infection
2%
Gangrene
2%
Sinusitis
2%
Hypertension
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
Sildenafil

Trial Design

1Treatment groups
Experimental Treatment
Group I: Sildenafil CitrateExperimental Treatment1 Intervention
Open label treatment with forced titration of sildenafil citrate.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Sildenafil Citrate
2021
Completed Phase 4
~1590

Find a Location

Who is running the clinical trial?

University of PennsylvaniaLead Sponsor
2,060 Previous Clinical Trials
42,647,599 Total Patients Enrolled
Boston UniversityOTHER
469 Previous Clinical Trials
9,955,073 Total Patients Enrolled
~1 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top